AAAAAA

   
Results: 1-9 |
Results: 9
SELECTIVITY OF THE MULTIDRUG-RESISTANCE MODULATOR, LY335979, FOR P-GLYCOPROTEIN AND EFFECT ON CYTOCHROME-P450 ACTIVITIES
Authors: DANTZIG AH SHEPARD RL LAW KL TABAS L GILLESPIE J BINKLEY S STARLING JJ WRIGHTON S
Citation: Ah. Dantzig et al., SELECTIVITY OF THE MULTIDRUG-RESISTANCE MODULATOR, LY335979, FOR P-GLYCOPROTEIN AND EFFECT ON CYTOCHROME-P450 ACTIVITIES, Annals of oncology, 9, 1998, pp. 555-555
NOVEL ACID-LABILE COL1 TRITYL-LINKED DIFLUORONUCLEOSIDE IMMUNOCONJUGATES - SYNTHESIS, CHARACTERIZATION, AND BIOLOGICAL-ACTIVITY
Authors: PATEL VF HARDIN JN MASTRO JM LAW KL ZIMMERMANN JL EHLHARDT WJ WOODLAND JM STARLING JJ
Citation: Vf. Patel et al., NOVEL ACID-LABILE COL1 TRITYL-LINKED DIFLUORONUCLEOSIDE IMMUNOCONJUGATES - SYNTHESIS, CHARACTERIZATION, AND BIOLOGICAL-ACTIVITY, Bioconjugate chemistry, 7(4), 1996, pp. 497-510
DEXTRAN MODIFICATION OF A FAB'-BETA-LACTAMASE CONJUGATE MODULATED BY VARIABLE PRETREATMENT OF FAB' WITH AMINE-BLOCKING REAGENTS
Authors: MIKOLAJCZYK SD MEYER DL FAGNANI R HAGAN MS LAW KL STARLING JJ
Citation: Sd. Mikolajczyk et al., DEXTRAN MODIFICATION OF A FAB'-BETA-LACTAMASE CONJUGATE MODULATED BY VARIABLE PRETREATMENT OF FAB' WITH AMINE-BLOCKING REAGENTS, Bioconjugate chemistry, 7(1), 1996, pp. 150-158
REVERSAL OF P-GLYCOPROTEIN-MEDIATED MULTIDRUG-RESISTANCE BY A POTENT CYCLOPROPYLDIBENZOSUBERANE MODULATOR, LY335979
Authors: DANTZIG AH SHEPARD RL CAO J LAW KL EHLHARDT WJ BAUGHMAN TM BUMOL TF STARLING JJ
Citation: Ah. Dantzig et al., REVERSAL OF P-GLYCOPROTEIN-MEDIATED MULTIDRUG-RESISTANCE BY A POTENT CYCLOPROPYLDIBENZOSUBERANE MODULATOR, LY335979, Cancer research, 56(18), 1996, pp. 4171-4179
SITE-SPECIFIC PRODRUG ACTIVATION BY ANTIBODY-BETA-LACTAMASE CONJUGATES - PRECLINICAL INVESTIGATION OF THE EFFICACY AND TOXICITY OF DOXORUBICIN DELIVERED BY ANTIBODY-DIRECTED CATALYSIS
Authors: MEYER DL LAW KL PAYNE JK MIKOLAJCZYK SD ZARRINMAYEH H JUNGHEIM LN KING JK SHEPHERD TA STARLING JJ
Citation: Dl. Meyer et al., SITE-SPECIFIC PRODRUG ACTIVATION BY ANTIBODY-BETA-LACTAMASE CONJUGATES - PRECLINICAL INVESTIGATION OF THE EFFICACY AND TOXICITY OF DOXORUBICIN DELIVERED BY ANTIBODY-DIRECTED CATALYSIS, Bioconjugate chemistry, 6(4), 1995, pp. 440-446
NOVEL TRITYL LINKED DRUG IMMUNOCONJUGATES FOR CANCER-THERAPY
Authors: PATEL VF HARDIN JN STARLING JJ MASTRO JM
Citation: Vf. Patel et al., NOVEL TRITYL LINKED DRUG IMMUNOCONJUGATES FOR CANCER-THERAPY, Bioorganic & medicinal chemistry letters, 5(5), 1995, pp. 507-512
HIGH-FIELD, SITE-SPECIFIC COUPLING OF N-TERMINALLY MODIFIED BETA-LACTAMASE TO A PROTEOLYTICALLY DERIVED SINGLE-SULFHYDRYL MURINE FAB'
Authors: MIKOLAJCZYK SD MEYER DL STARLING JJ LAW KL ROSE K DUFOUR B OFFORD RE
Citation: Sd. Mikolajczyk et al., HIGH-FIELD, SITE-SPECIFIC COUPLING OF N-TERMINALLY MODIFIED BETA-LACTAMASE TO A PROTEOLYTICALLY DERIVED SINGLE-SULFHYDRYL MURINE FAB', Bioconjugate chemistry, 5(6), 1994, pp. 636-646
IN-VIVO EXPRESSION OF P-GLYCOPROTEIN IN A HUMAN COLON-CARCINOMA XENOGRAFT IS MODULATED BY THERAPY WITH FREE AND MONOCLONAL ANTIBODY-CONJUGATED VINCA ALKALOIDS
Authors: KANITZ MHH MASTRO JM MOORE RE STARLING JJ
Citation: Mhh. Kanitz et al., IN-VIVO EXPRESSION OF P-GLYCOPROTEIN IN A HUMAN COLON-CARCINOMA XENOGRAFT IS MODULATED BY THERAPY WITH FREE AND MONOCLONAL ANTIBODY-CONJUGATED VINCA ALKALOIDS, Anticancer research, 14(3A), 1994, pp. 857-868
SITE-SPECIFIC PRODRUG ACTIVATION BY ANTIBODY-BETA-LACTAMASE CONJUGATES - REGRESSION AND LONG-TERM GROWTH-INHIBITION OF HUMAN COLON-CARCINOMA XENOGRAFT MODELS
Authors: MEYER DL JUNGHEIM LN LAW KL MIKOLAJCZYK SD SHEPHERD TA MACKENSEN DG BRIGGS SL STARLING JJ
Citation: Dl. Meyer et al., SITE-SPECIFIC PRODRUG ACTIVATION BY ANTIBODY-BETA-LACTAMASE CONJUGATES - REGRESSION AND LONG-TERM GROWTH-INHIBITION OF HUMAN COLON-CARCINOMA XENOGRAFT MODELS, Cancer research, 53(17), 1993, pp. 3956-3963
Risultati: 1-9 |